EWTX Price Prediction Next Week
Analysis and Insights
Technical Analysis:
EWTX's stock price has shown bearish momentum recently, with the price crossing below the 200-day moving average, a significant bearish signal. The stock closed at $23.38 on 2025-03-24, with a 52-week range of $14.90 to $38.12. The Relative Strength Index (RSI) is at 37.36, indicating the stock is near oversold territory but not yet oversold. The MACD is negative, suggesting bearish momentum.
Fibonacci Levels:
The Fibonacci levels indicate a pivot point at $25.78, with resistance at $27.80 and support at $23.77. The stock is currently trading below the pivot point, which could indicate further downside.
Options Activity:
There has been significant options activity, with 7,570 contracts traded, particularly focused on the $20 strike put option expiring April 17, 2025. This high volume of put contracts suggests bearish sentiment among investors.
Analyst Sentiment:
Analysts have a Strong Buy rating on EWTX, with an average price target of $47.43, indicating a potential 65.8% upside from current levels. However, this is a longer-term view, and short-term technical indicators suggest caution.
Prediction and Recommendation:
Based on the technical indicators, Fibonacci levels, and options activity, the stock is expected to decline in the next trading week. The predicted price target is $22.50, with the stock likely to test the lower support levels.
Recommendation: Sell EWTX at the current price of $23.38, with a target price of $22.50.
EWTX Similar Chart Price Prediction
The price of EWTX is predicted to go up 7.35%, based on the high correlation periods with VICR. The similarity of these two price pattern on the periods is 91.58%.
EWTX
VICR
Up: 7.35%Similarity: 91.58%
EWTX Revenue Forecast
EWTX EPS Forecast
EWTX Analyst's Forecast
James Condulis
Stifel
Hold
2025-01-22
Price Target
$30
Upside
+10.54%
Stifel initiated coverage of Edgewise Therapeutics with a Hold rating and $30 price target. The firm says that while Edgewise has "very interesting science" with two clinical-stage assets, its thesis reflects a view that clinical data for both EDG-7500 and sevasemten are early, and there remains "real risk" to the "target-product-profile" for each. The window to clearly differentiate from aficamten is narrow and the path to doing so "is tricky," the analyst tells investors in a research note.
Cory Kasimov
Evercore ISI Group
Buy
2024-12-17
Price Target
$45 → $50
Upside
+65.73%
Srikripa Devarakonda
Truist Securities
Strong Buy
2024-11-27
Price Target
$33 → $50
Upside
+55.28%
